Taysha Gene Therapies, Inc. Operating Lease, Payments
Taysha Gene Therapies, Inc. (TSHA) reported Operating Lease, Payments of $3.02 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-19
- Taysha Gene Therapies, Inc. operating lease, payments for the quarter ending 2024-12-31 was $713.00K, a 0.28% decline year-over-year.
- Taysha Gene Therapies, Inc. operating lease, payments for the quarter ending 2024-09-30 was $711.00K, a 48.74% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, payments for the quarter ending 2024-06-30 was -$1.35M, a 243.88% decline year-over-year.
- Taysha Gene Therapies, Inc. operating lease, payments for the quarter ending 2024-03-31 was $2.74M, a 296.24% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, payments for fiscal 2025 was $3.02M, a 7.25% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. operating lease, payments for fiscal 2024 was $2.81M, a 0.32% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. operating lease, payments for fiscal 2023 was $2.82M, a 13.60% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. operating lease, payments for fiscal 2022 was $2.49M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.02M 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.42M derived: sum of 2 quarters · filed 2026-03-19 | $73.00K derived: sum of 3 quarters · filed 2026-03-19 | $2.81M 10-K · filed 2026-03-19 |
| 2024-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$640.00K derived: sum of 2 quarters · filed 2024-11-13 | $2.10M 10-Q · filed 2024-11-13 | $2.82M derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-06-30 | -$1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.39M 10-Q · filed 2024-08-12 | $2.11M derived: sum of 3 quarters · filed 2025-02-26 | $2.58M derived: sum of 4 quarters · filed 2025-02-26 |
| 2024-03-31 | $2.74M 10-Q · filed 2024-05-14 | $3.46M derived: sum of 2 quarters · filed 2025-02-26 | $3.94M derived: sum of 3 quarters · filed 2025-02-26 | $4.87M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-12-31 | $715.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.19M derived: sum of 2 quarters · filed 2025-02-26 | $2.13M derived: sum of 3 quarters · filed 2025-02-26 | $2.82M 10-K · filed 2025-02-26 |
| 2023-09-30 | $478.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.42M derived: sum of 2 quarters · filed 2024-11-13 | $2.11M 10-Q · filed 2024-11-13 | $3.75M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $939.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.63M 10-Q · filed 2024-08-12 | $3.27M derived: sum of 3 quarters · filed 2024-08-12 | $3.39M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $692.00K 10-Q · filed 2024-05-14 | $2.33M derived: sum of 2 quarters · filed 2024-05-14 | $2.45M derived: sum of 3 quarters · filed 2024-05-14 | $2.81M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.76M derived: sum of 2 quarters · filed 2024-03-19 | $2.12M derived: sum of 3 quarters · filed 2024-03-19 | $2.49M 10-K · filed 2024-03-19 |
| 2022-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $484.00K derived: sum of 2 quarters · filed 2023-11-14 | $847.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $363.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $726.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $363.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |